Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

doi: 10.1021/acs.jnatprod.1c00946.

Online ahead of print.

Richard B van Breemen¹, Ruth N Muchiri¹, Timothy A Bates², Jules B Weinstein², Hans C Leier², Scotland Farley², Fikadu G Tafesse²

Affiliations

PMID: 35007072
DOI: 10.1021/acs.jnatprod.1c00946

Abstract

As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection-mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.

Similar articles

Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19).

Aleem A, Akbar Samad AB, Slenker AK.2022 Jan 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 34033342 Free Books & Documents. Review.
Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.

Acharya A, Pandey K, Thurman M, Klug E, Trivedi J, Sharma K, Lorson CL, Singh K, Byrareddy SN.J Virol. 2021 Nov 23;95(24):e0143721. doi: 10.1128/JVI.01437-21. Epub 2021 Sep 22.PMID: 34550770 Free PMC article.
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.

Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, Di Emidio P, Tetè G, Pregliasco F, Ronconi G.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.PMID: 33377359
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.

Melo-González F, Soto JA, González LA, Fernández J, Duarte LF, Schultz BM, Gálvez NMS, Pacheco GA, Ríos M, Vázquez Y, Rivera-Pérez D, Moreno-Tapia D, Iturriaga C, Vallejos OP, Berríos-Rojas RV, Hoppe-Elsholz G, Urzúa M, Bruneau N, Fasce RA, Mora J, Grifoni A, Sette A, Weiskopf D, Zeng G, Meng W, González-Aramundiz JV, González PA, Abarca K, Ramírez E, Kalergis AM, Bueno SM.Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021.PMID: 34858404 Free PMC article. Clinical Trial.
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.

Khan WH, Hashmi Z, Goel A, Ahmad R, Gupta K, Khan N, Alam I, Ahmed F, Ansari MA.Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.PMID: 34568087 Free PMC article. Review.